Abstract: Precut, user-shapeable, resorbable polymer micro-membranes are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions and to be absorbed into the body relatively slowly over time. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures.

Abstract: Precut, user-shapeable, resorbable polymer micro-membranes having cusped orifices are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures.

Abstract: Precut, user-shapeable, resorbable polymer micro-membranes are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions and to be absorbed into the body relatively slowly over time. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures.

Abstract: Precut, user-shapeable, resorbable polymer micro-membranes having cusped orifices are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures.

Abstract: Benzylselenobenzamides of formula I ##STR1## with inflammation-inhibiting characteristics and used in pharmaceutical preparations.

Abstract: The invention relates to a new process for the treatment of hypertension and thromboembolic diseases in humans by simultaneous administration of (.+-.)- or (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene hydrochloride on the one side, and 4,5-dihydro-6-[4-(1-imidazolyl)-phenyl]-5-methyl-3(2H)-pyridazinone or 4,5-dihydro-6-[4-(1-imidazolyl)-thien-2-yl]-5-methyl-3(2H)-pyridazinone, on the other side, as the active substances.

Abstract: The present invention is related to new S-(Carbamoyl-phenylselenyl) derivatives of mercaptanes of the general formula (I) ##STR1## and to a process for the treatment of diseases caused by cell injury due to the increased formation of active oxygen metabolites.

Abstract: An electromagnetically actuatable pressure modulator for anti-locking brake systems utilizes a variable lever-type transmission interposed between a pressure relief piston of the modulator and the compression spring biased armature of an electromagnet whereby the non-linear force/air-gap relationship of the electromagnet is converted to a linear variation of the force applied to the pressure relief piston for moving same. When a predetermined maximum brake pressure is applied to the modulator, the latter automatically isolates the wheel cylinder from the master cylinder.

Abstract: The invention relates to a new process for the treatment of hypertension and thromboembolic diseases in humans by simultaneous administration of (.+-.)- or (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene hydrochloride on the one side, and 4,5-dihydro-6-[4-(1-imidazolyl)-phenyl]-5-methyl-3(2H)-pyridazinone or 4,5-dihydro-6-[4-(1-imidazolyl)-thien-2-yl]-5-methyl-3(2H)-pyridazinone, on the other side, as the active substances.

Abstract: The present invention relates to new S-(carbamoylphenylselenyl) derivatives of glutathione and of .alpha.

Abstract: The invention relates to new O-acyl-alkanediol-phospholipids of the general formula I ##STR1## processes for their preparation and process for the treatment of certain diseases in humans.

Abstract: The present invention is directed to a new process for the treatment of inflammatory diseases and disorders in humans by administering a pharmaceutical preparation containing rosmarinic acid.

Abstract: (3-Alkylamino-2-hydroxypropoxy)-furan-2-carboxylic acid anilides of the formula: ##STR1## in which R.sub.1 denotes a straight or branched C.sub.1 to C.sub.5 alkyl group or a cyclopropyl or cyclopentyl group, R.sub.2 denotes a hydrogen or halogen atom or a methyl, methoxy, nitro or acetyl group, R.sub.3 denotes a hydrogen or halogen atom or a nitro group and A denotes a single bond or the --CH.sub.2 -- or --CH.dbd.CH-- group, and physiologically tolerated acid addition salts thereof possess .beta.-adrenolytic properties and a low toxicity.